<DOC>
	<DOCNO>NCT00003764</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know whether combine cyclophosphamide fludarabine effective fludarabine alone treat chronic lymphocytic leukemia . PURPOSE : Randomized phase III trial study effectiveness fludarabine without cyclophosphamide treat patient chronic lymphocytic leukemia treat previously .</brief_summary>
	<brief_title>Fludarabine With Without Cyclophosphamide Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy fludarabine without cyclophosphamide term complete remission rate overall survival patient previously untreated B cell chronic lymphocytic leukemia ( CLL ) . - Compare toxicities 2 regimen patient population . - Determine whether expression protein specifically implicate regulation DNA damage induce apoptosis lymphoid cell ( i.e. , p53 ; mdm2 ; GST ; Bcl-2 ; Mcl-1 ; Bax ; p27 ; caspase-3 ) correlate response chemotherapy patient . - Determine whether relationship clinical response resistance differential expression gene CLL cell either initiation therapy follow relapse progression . - Correlate mutation immunoglobulin heavy chain variable region gene clinical response resistance patient population . OUTLINE : This randomize , multicenter study . Patients stratify accord stage disease ( O-II v III-IV ) . Patients randomize one two treatment arm . - Arm I : Patients receive fludarabine IV 30 minute day 1-5 . - Arm II : Patients receive fludarabine arm I plus cyclophosphamide IV 1 hour day 1 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month disease progression . PROJECTED ACCRUAL : A total 280 patient accrue study 2 2.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) stage define follow : Peripheral blood absolute lymphocyte count great 5,000/mm^3 within 14 day prior study Lymphocytes must small moderate size 55 % prolymphocytes , atypical lymphocyte , lymphoblast morphologically Phenotypically characterize BCLL Must one follow characteristic indicate need chemotherapy : Progressive marrow failure ( hemoglobin le 10 g/dL and/or platelet count le 100,000/mm^3 ) Progressive lymphocytosis increase 50 % 2 month period anticipate doubling time le 6 month Massive ( i.e. , great 6 cm leave costal margin ) progressive splenomegaly Massive nod cluster ( i.e. , great 10 cm long diameter ) progressive adenopathy At least 10 % weight loss within 6 month study Extreme fatigue Fevers great 100.5 degree F 2 week without evidence infection Night sweat without evidence infection No autoimmune anemia autoimmune thrombocytopenia PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2 mg/dL unless secondary tumor Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 40 mL/min creatinine great 1.5 mg/dL Other : No prior concurrent malignancy within past 2 year except basal cell carcinoma skin carcinoma situ cervix No active infection require oral intravenous antibiotic Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy Endocrine therapy : No prior steroid treatment CLL Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>